Showing results 1 to 20 of 39
next >
| Issue Date | Title | Author(s) |
| 2018 | Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study | Li, Jin; Xu, Ruihua; Qin, Shukui; Liu, Tianshu; Pan, Hongming; Xu, Jianming; Bi, Feng; Lim, Robert; Zhang, Suzhan; Ba, Yi; Bai, Yuxian; Fan, Nanfeng; Tsuji, Akihito; Yeh, Kun-Huei; Ma, Brigette; Wei, Vivian; Shi, Dongmei; Magherini, Emmanuelle; Shen, Lin |
| 2019 | Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. | Li, Jin; Qin, Shukui; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Ruihua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhu, Chao; Fan, Songhua; Gong, Wei; Wang, Wei |
| 20-May-2020 | Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. | Xu, Jianming; Liu, Tianshu; Lee, Jong-Seok; Bai, Yuxian; Chao, Yee; Yang, Silu; Zhang, Yun; Ma, Xiaopeng; Zhang, Pei; Zheng, Jianfei; Li, Yanyan; Wang, Jin; Shen, Lin |
| May-2021 | Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma | Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei; Han, Weiqing; Dong, Haiying; Guo, Jianming; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Ouyang, Weiwei; Ma, Lulin; Sun, Yan; Zhang, Feng; Lv, Jun; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Wang, Xiang; Liu, Zhen; Shen, Lin |
| 20-May-2020 | Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+line metastatic colorectal carcinoma (mCRC) phase III trial. | Bai, Yuxian; Qin, Shukui; Li, Jin; Deng, Yanhong; Yang, Lei; Xu, Rui-hua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhang, Bin; Zhang, Qiang; Fan, Songhua; Guo, Xiaojun; Peng, Mengye |
| 2018 | Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial | Li, Jin; Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Hua, Ye; Su, Weiguo |
| 2014 | Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study | Qin, Shukui; Cheng, Ying; Liang, Jun; Shen, Lin; Bai, Yuxian; Li, Jianfeng; Fan, Jia; Liang, Luian; Zhang, Yaqi; wu, Gang; Rau, Kun-Ming; Yang, Tsai-Shen; Jian, Zhixiang; Liang, Houjie; Sun, Yan |
| Jul-2021 | First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis. | Shen, Lin; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Liu, Tianshu |
| Oct-2022 | First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis | Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin |
| Feb-2024 | Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study. | Xu, Rui-Hua; Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Su, Weiguo |
| Aug-2020 | GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial | Shen, Lin; Gong, Jifang; Song, Yuqin; Ye, Dingwei; Lu, Zhihao; Wang, Siyang; Peng, Peijian; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Bai, Yuxian; Pan, Jianji; Ma, Chunguang; Chen, Li; Ma, Yi; Li, Qi; Lu, Ping; Zhang, Lingli; Yin, Xianli; Gu, Shanzhi; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Cao, Bangwei; Han, Weiqing; Sun, Yan; Zhang, Feng; Ouyang, Weiwei; Dong, Haiying; Guo, Jianming; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Lv, Jun; Wang, Xiang; Chen, Chris; Li, Jing; Zheng, Yong; Jin, Ge; Yang, Yining; Zhao, Guodong; Yang, Fan; Xu, Kehui; Liang, Xiangying; Pan, Zhaoyang; Meng, Haijin |
| 20-May-2020 | Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors. | Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
| Dec-2021 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer | Janjigian, Yelena Y.; Kawazoe, Akihito; Yanez, Patricio; Li, Ning; Lonardi, Sara; Kolesnik, Oleksii; Barajas, Olga; Bai, Yuxian; Shen, Lin; Tang, Yong; Wyrwicz, Lucjan S.; Xu, Jianming; Shitara, Kohei; Qin, Shukui; Van Cutsem, Eric; Tabernero, Josep; Li, Lie; Shah, Sukrut; Bhagia, Pooja; Chung, Hyun Cheol |
| 2014 | The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma | Gong, Jifang; Hu, Bing; Zhang, Xiaotian; Zhang, Fengchun; Zhang, Jun; Xu, Nong e; Fan, Qingxia; Bai, Yuxian; Jiao, Shunchang; Wang, Jinwan; Bai, Chunmei; Zheng, Leizhen; Shi, Yingqiang; Liu, Yunpeng; Liang, Jun; Hu, Guoqing; Cheng, Ying; Xu, Ruihua; Bai, Yu; Shen, Lin |
| 2014 | A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity. | Gong, Jifang; Liu, Tianshu; Fan, Qingxia; Bai, Li; Bi, Feng; Qin, Shukui; Wang, Jinwan; Xu, Nong; Cheng, Ying; Bai, Yuxian; Liu, Wei; Wang, Liwei; Shen, Lin |
| 2016 | Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial | Gong, Jifang; Liu, Tianshu; Fan, Qingxia; Bai, Li; Bi, Feng; Qin, Shukui; Wang, Jinwan; Xu, Nong; Cheng, Ying; Bai, Yuxian; Liu, Wei; Wang, Liwei; Shen, Lin |
| Mar-2025 | Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) final report of a randomi | Zhang, Xiaotian; Liang, Han; Li, Ziyu; Xue, Yingwei; Wang, Yanong; Zhou, Zhiwei; Yu, Jiren; Bu, Zhaode; Chen, Lin; Du, Yian; Wang, Xinbao; Wu, Aiwen; Li, Guoli; Su, Xiangqian; Xiao, Gang; Cui, Ming; Wu, Dan; Chen, Li; Wu, Xiaojiang; Zhou, Yanbing; Zhang, Lianhai; Dang, Chengxue; He, Yulong; Zhang, Zhongtao; Sun, Yihong; Li, Yong; Chen, Huanqiu; Bai, Yuxian; Wang, Yakun; Yu, Peiwu; Zhu, Guanbao; Suo, Jian; Jia, Baoqing; Li, Leping; Huang, Changming; Li, Fei; Ye, Yingjiang; Xu, Huimian; Wang, Xin; Yuan, Yannan; Jianyu, E.; Ying, Xiangji; Yao, Chen; Shen, Lin; Ji, Jiafu |
| Aug-2021 | Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiori | Zhang, Xiaotian; Liang, Han; Li, Ziyu; Xue, Yingwei; Wang, Yanong; Zhou, Zhiwei; Yu, Jiren; Bu, Zhaode; Chen, Lin; Du, Yian; Wang, Xinbao; Wu, Aiwen; Li, Guoli; Su, Xiangqian; Xiao, Gang; Cui, Ming; Wu, Dan; Chen, Li; Wu, Xiaojiang; Zhou, Yanbing; Zhang, Lianhai; Dang, Chengxue; He, Yulong; Zhang, Zhongtao; Sun, Yihong; Li, Yong; Chen, Huanqiu; Bai, Yuxian; Qi, Changsong; Yu, Peiwu; Zhu, Guanbao; Suo, Jian; Jia, Baoqing; Li, Leping; Huang, Changming; Li, Fei; Ye, Yingjiang; Xu, Huimian; Wang, Xin; Yuan, Yannan; Jian-Yu, E.; Ying, Xiangji; Yao, Chen; Shen, Lin; Ji, Jiafu |
| 2019 | Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial | Liu, Tianshu; Qin, Yanru; Li, Jin; Xu, Ruihua; Xu, Jianming; Yang, Shujun; Qin, Shukui; Bai, Yuxian; Wu, Changping; Mao, Yixiang; Wu, Haiyan; Ge, Yilin; Shen, Lin |
| Aug-2022 | Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma | Ren, Zhengang; Shao, Guoliang; Shen, Jie; Zhang, Li; Zhu, Xu; Fang, Weijia; Sun, Guoping; Bai, Yuxian; Wu, Jianbing; Liu, Lianxin; Yuan, Yuan; Zhang, Jingdong; Li, Zhen; Zhang, Ling; Yin, Tao; Wu, Jincai; Hou, Xiaoli; Wang, Qingyu; Zhu, Jun; Fan, Jia; Serplulimab-HCC Investigators |
